• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Recent advances in immunotherapy for the treatment of prostate cancer.
【24h】

Recent advances in immunotherapy for the treatment of prostate cancer.

机译：免疫疗法治疗前列腺癌的最新进展。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Prostate cancer vaccines attempt to induce cancer-specific systemic immune responses and represent a new class of targeted therapies, many of which are non-toxic. Several vaccine technologies are in development. AREAS COVERED: An autologous antigen presenting cell vaccine loaded with prostate acid phosphatase conjugated with GM-CSF, sipuleucel-T confers a survival advantage in men with metastatic castration-resistant prostate cancer (CRPC) and is now FDA approved based on the IMPACT trial. A poxvirus-based vaccine, PROSTVAC-VF TRICOM targeting prostate-specific antigen (PSA), has demonstrated improved survival in a randomized Phase II trial of patients with metastatic CRPC. Novel T lymphocyte checkpoint inhibitors of cytotoxic T lymphocyte antigen 4 and programmed death-1 are also emerging. Recognition of improved survival without an earlier clinical signal of activity by conventional criteria has led to new guidelines to evaluate immunotherapeutic agents. The clinical benefit of combining vaccines with chemotherapy, radiotherapy and other immunotherapeutic and biologic agents is being evaluated in the context of disappointing results of combination GVAX vaccine and docetaxel chemotherapy. EXPERT OPINION: To build on the success of early phase trials, efforts must be made to optimize vaccine approaches and patient selection.
机译：简介：前列腺癌疫苗试图诱导癌症特异性的全身免疫反应，并代表了一类新型的靶向疗法，其中许多是无毒的。几种疫苗技术正在开发中。覆盖的区域：sipuleucel-T自体抗原呈递细胞疫苗载有与GM-CSF缀合的前列腺酸磷酸酶，sipuleucel-T在转移性去势抵抗性前列腺癌（CRPC）男性中具有生存优势，目前已根据IMPACT试验获得FDA批准。一种针对痘病毒的疫苗，针对前列腺特异性抗原（PSA）的PROSTVAC-VF TRICOM，已在转移性CRPC患者的II期随机试验中显示了改善的生存率。还出现了新型的细胞毒性T淋巴细胞抗原4和程序性死亡1的T淋巴细胞检查点抑制剂。通过常规标准认识到在没有较早的临床活动信号的情况下存活率的提高已导致评估免疫治疗剂的新指南。在将GVAX疫苗和多西他赛化疗联合使用的结果令人失望的情况下，正在评估将疫苗与化疗，放疗以及其他免疫治疗和生物制剂联合使用的临床益处。专家意见：为了在早期试验的成功基础上，必须努力优化疫苗方法和患者选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号